9.89
-0.2(-1.98%)
Currency In USD
| Previous Close | 10.09 |
| Open | 9.93 |
| Day High | 10.32 |
| Day Low | 9.58 |
| 52-Week High | 23.4 |
| 52-Week Low | 3.52 |
| Volume | 2.07M |
| Average Volume | 2.08M |
| Market Cap | 452.05M |
| PE | -7.22 |
| EPS | -1.37 |
| Moving Average 50 Days | 10.49 |
| Moving Average 200 Days | 12.82 |
| Change | -0.2 |
If you invested $1000 in Capricor Therapeutics, Inc. (CAPR) 10 years ago, it would be worth $160.03 as of June 01, 2025 at a share price of $9.89. Whereas If you bought $1000 worth of Capricor Therapeutics, Inc. (CAPR) shares 5 years ago, it would be worth $2,056.13 as of June 01, 2025 at a share price of $9.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Caprock Plans to Test Deep-Seated High-Grade Mineralization at Its Destiny Project This Summer
Newsfile
May 22, 2025 12:00 PM GMT
Toronto, Ontario--(Newsfile Corp. - May 22, 2025) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to provide details of an initial exploration drill program this summer at its flagship Destiny gold property ("Destiny" or th
Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
GlobeNewswire Inc.
May 13, 2025 1:00 PM GMT
— Dr. Binks joins Capricor in anticipation of potential approval of deramiocel in Q3 2025, bringing extensive experience in neuromuscular and rare diseases —SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotech
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
GlobeNewswire Inc.
May 06, 2025 1:15 PM GMT
Company to Host Conference Call, May 13, 2025 at 4:30 p.m. ETSAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment o